ClinicalTrials.gg
Sign In

Drug

Olomorasib clinical trials

Also written LY3537982.

studies test it
15
open now
5
in phase 3
2
first study started
2023

Keep track of what changes. Save the olomorasib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Name

Olomorasib
12

Development codes

LY3537982
14

Studies by the year they started

15 studies that test it; most in 2026 (5)

Studies that test olomorasib, by start year
YearStudies
20234
20242
20254
20265

By phase

A phase 1/2 study counts in both.

Phase 1
11
Phase 2
3
Phase 3
2

What it is tested for

Each study’s main condition, where its own words name it.

Carcinoma, Non-Small-Cell Lung
4
Renal Insufficiency
1
Hepatic Insufficiency
1
Colorectal Neoplasms
1

Who runs them

Industry 14 · Other 1

Eli Lilly and Company (13) · Janssen Research & Development, LLC (1) · UNC Lineberger Comprehensive Cancer Center (1)

Often tested with

Tested in the same studies.

Pembrolizumab (2) · Fluconazole (1) · Digoxin (1) · Rosuvastatin (1) · Midazolam (1) · Cetuximab (1) · Pemetrexed (1) · Durvalumab (1)

Studies

Open first, then newest update. How each study uses olomorasib is read from its arms, and is right about nine times in ten.

Testing it · 15

Given in every arm · 3 — olomorasib is usual care beside what is tested

Codes

What other systems call olomorasib · ClinicalTrials.gg INT016158

  • UNII (FDA) C2VJ83PSN7OLOMORASIBConfirmed FDA, Wikidata
  • Wikidata Q133445577olomorasibConfirmed FDA, Wikidata
  • NCI Thesaurus C181751OlomorasibOne source FDA
  • DrugBank DB21697One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.